Knowledge-graph-based strategies identified baricitinib, originally developed for the treatment of rheumatoid arthritis, as a candidate for treating COVID-19 by blocking JAK1, JAK2, adaptor associated kinase 1 (AAK1), and cyclin G-associated kinase [72]. Here, AAK1 is linked to rheumatoid arthritis.